Understanding When To Treat Nonmetastatic Crpc
Exploring When To Treat Nonmetastatic Crpc reveals several interesting facts. Julie Graff, MD, discusses the case of the 66-year-old male patient after a 2-year follow up and explains how to decide
Key Takeaways about When To Treat Nonmetastatic Crpc
- Trials are underway to investigate the role of nonsteroidal antiandrogens in
- Atish D. Choudhury, MD, PhD, discusses antiandrogen
- Raoul S. Concepcion, MD, FACS; Neal D. Shore, MD, FACS; Daniel George, MD; and Alec Koo, MD, define castration-resistant ...
- Matthew R. Smith, MD, PhD, defines
- Charles Ryan, MD, reviews the case of a 62-year-old male patient with
Detailed Analysis of When To Treat Nonmetastatic Crpc
Charles Ryan, MD, describes the data for ARN-509, including safety and efficacy, and how its approval will change ... patients some of these patients end up developing another progression what we call Julie Graff, MD, reviews the case of a 66-year-old male patient with
Judd W. Moul, MD; Julie Graff, MD; and Charles J. Ryan, MD, highlight which approaches most excite them in the future
Stay tuned for more updates related to When To Treat Nonmetastatic Crpc.